In the latest trading session, 0.51 million Twist Bioscience Corp (NASDAQ:TWST) shares changed hands as the company’s beta touched 1.43. With the company’s most recent per share price at $25.61 changing hands around $1.6 or 6.68% at last look, the market valuation stands at $1.47B. TWST’s current price is a discount, trading about -23.04% off its 52-week high of $31.51. The share price had its 52-week low at $11.46, which suggests the last value was 55.25% up since then. When we look at Twist Bioscience Corp’s average trading volume, we note the 10-day average is 1.34 million shares, with the 3-month average coming to 984.49K.
Analysts gave the Twist Bioscience Corp (TWST) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 1.91. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 2 assigning it an Overweight rating. Of the remaining, 2 recommended TWST as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Twist Bioscience Corp’s EPS for the current quarter is expected to be -$0.78.
Twist Bioscience Corp (NASDAQ:TWST) trade information
Instantly TWST is in green as seen in intraday trades today. With action 48.41%, the performance over the past five days has been green. The jump to weekly highs of 25.78 on Friday, 11/17/23 added 6.68% to the stock’s daily price. The company’s shares are showing year-to-date upside of 7.58%, with the 5-day performance at 48.41% in the green. However, in the 30-day time frame, Twist Bioscience Corp (NASDAQ:TWST) is 52.93% up. Looking at the short shares, we see there were 14.96 million shares sold at short interest cover period of 16.79 days.
The consensus price target for the stock as assigned by Wall Street analysts is $27.78, meaning bulls need an upside of 7.81% from its recent market value. According to analyst projections, TWST’s forecast low is $19.00 with $33.00 as the target high. To hit the forecast high, the stock’s price needs a -28.86% plunge from its current level, while the stock would need to tank 25.81% for it to hit the projected low.
Twist Bioscience Corp (TWST) estimates and forecasts
Data shows that the Twist Bioscience Corp share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 71.57% over the past 6 months, a 12.71% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Twist Bioscience Corp will fall -5.40%, while the growth in revenue is estimated to hit 27.90% for the next quarter. Year-over-year growth is forecast to reach 19.50% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of $66.79 million. 8 analysts are of the opinion that Twist Bioscience Corp’s revenue for the quarter ending Mar 2024 will be $69.9 million.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -6.09%. The 2023 estimates are for Twist Bioscience Corp earnings to increase by 17.89%.
Twist Bioscience Corp is expected to release its next quarterly earnings report between February 01 and February 05.
Twist Bioscience Corp (NASDAQ:TWST)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.59% of Twist Bioscience Corp shares while 108.82% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.57%. There are 108.82% institutions holding the Twist Bioscience Corp stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 12.03% of the shares, roughly 6.91 million TWST shares worth $141.28 million.
ARK Investment Management, LLC holds the second largest percentage of outstanding shares, with 11.82% or 6.79 million shares worth $137.48 million as of Sep 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and ARK ETF Tr-ARK Innovation ETF. With 3.49 million shares estimated at $76.77 million under it, the former controlled 6.08% of total outstanding shares. On the other hand, ARK ETF Tr-ARK Innovation ETF held about 6.06% of the shares, roughly 3.48 million shares worth around $70.48 million.